Egetis Therapeutics Q1 2024: Initial comment - Redeye

Redeye notes that Egetis’ Q1 report presented SEK12.1m in revenues and SEK-78.2m in operating expenses, and offered no material surprises. 13 out of (at least) 16 patients have been recruited in the ongoing US registrational ReTRIACt trial and Egetis is in the process of addressing the EMA's 120-day list of questions relating to the ongoing EU application, expected to be submitted in August. We will return on Monday with a research update but don’t expect to make any significant changes.

Länk till analysen i sin helhet: https://www.redeye.se/research/1002175/egetis-therapeutics-q1-2024-initial-comment?utm_source=finwire&utm_medium=RSS